All eosinophilic esophagitis articles
-
NewsNew Phase III Tezspire data signals advance in epithelial-driven inflammatory disease treatment
First-in-class monoclonal antibody significantly improved both underlying inflammation and dysphagia in eosinophilic esophagitis, extending its potential beyond the airways to the oesophagus.
-
NewsFirst-of-a-kind EU approval granted for eosinophilic esophagitis medicine
With its novel approach for addressing a fundamental cause of eosinophilic esophagitis, approval of the biologic marks a potential new standard of care for paediatric patients.
-
NewsEosinophilic esophagitis medicine approval expanded
Approval of the first treatment for patients one year old and over with eosinophilic esophagitis (EoE) was based on trial data showing a greater proportion of children given Dupixent achieved histological remission compared to placebo.
-
NewsFirst medicine approved in EU for eosinophilic esophagitis
Dupixent® has been approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis.